Kashyap Patel, MD, a medical oncologist at Carolina Blood and Cancer Care, said after the FDA’s Oncologic Drug Advisory Committee (ODAC) hearing on CT-P10 that "Clearly, the mood has changed to be a lot more favorable for the biosimilars.”
Earlier this week, the FDA’s Oncologic Drug Advisory Committee (ODAC) held an open public hearing to discuss the Biologics License Application for CT-P10, Celltrion’s proposed rituximab biosimilar. The committee voted unanimously to recommend approval of the dug based on evidence from 2 confirmatory safety and efficacy trials.
Among stakeholders who testified in support of approving CT-P10 was Kashyap Patel, MD, a medical oncologist at Carolina Blood and Cancer Care. Patel told The Center for Biosimilars® in an interview following the hearing that much has changed since last year’s ODAC hearing on the anticancer biosimilars trastuzumab and bevacizumab.
In the July 2017 proceedings, some stakeholders highlighted concerns about postapproval pharmacovigilance efforts for biosimilars, and about clinical trial design for the products. However, in this week’s hearing, said Patel, “Clearly, the mood has changed to be a lot more favorable for the biosimilars.”
Patel described the hearing as “upbeat” about the prospective licensure of the drug, and noted that drug developer Celltrion had done a thorough job of addressing the FDA’s concerns with its data, and very little discussion centered around concerns about the safety or immunogenicity of the product. The FDA, too, said Patel, did well to thoroughly assess the drug’s data and to clearly communicate the meaning of the totality of the evidence supporting approval.
While Celltrion indicated during the hearing that it was only seeking 3 indications for its biosimilar product as a result of the patents covering the brand-name Rituxan, Patel indicated that he would not be surprised to see physicians adopt the biosimilar for other indications on the basis of extrapolation. He noted that, in oncology, approximately one-third of product use is based on either extrapolation or a compendium listing, and it would not be unlikely that, with growing concerns about cost and growing acceptance of biosimilars, CT-P10 could find its way to patients who need treatment for indications outside of those sought by Celltrion.
In looking to his own practice, Patel is enthusiastic about the potential for the biosimilar to result in increased access and affordability of anticancer treatment for his patients. In his rural practice setting, approximately 20% of Patel’s patients are underinsured, and some face the choice between putting food on the table and paying for their care. “This will not solve it all,” Patel said, but a cheaper anticancer therapeutic would help to ease these patients’ financial burdens related to their out-of-pocket costs.
Patel also sees clear benefits for his practice. As an Oncology Care Model (OCM) participant, his practice has already seen substantial cost savings from using biosimilar filgrastim instead of its reference in treating and preventing febrile neutropenia associated with myelosuppressive chemotherapy. In fact, 7% of the practice’s OCM savings came from biosimilar use alone. Using biosimilar rituximab, he indicated, could help to produce even further savings.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.